公开(公告)号：US09716757B2

公开(公告)日：2017-07-25

申请号：US14295548

申请日：2014-06-04

申请人： Philippe Fernandes

发明人： Philippe Fernandes

IPC分类号： G06F15/16 ,  H04L29/08 ,  A61M16/00 ,  A61M1/00 ,  A61M11/00 ,  A61B5/00 ,  A61M16/10

CPC分类号： H04L67/12 ,  A61B5/0022 ,  A61B5/4818 ,  A61B5/7257 ,  A61B2560/0271 ,  A61B2560/028 ,  A61M1/00 ,  A61M11/00 ,  A61M16/0051 ,  A61M16/021 ,  A61M16/101 ,  A61M2202/0208 ,  A61M2205/3375 ,  A61M2205/3553 ,  A61M2205/3592 ,  A61M2205/52 ,  G06F19/00 ,  G16H40/67

摘要： A device (9) for remotely monitoring at least one medical device (7) includes at least one portion (11) that vibrates when the medical device is used by a patient in order to receive a medical treatment. The monitoring device (9) includes: at least one sensor (15) intended to be in mechanical contact with the portion and suitable for detecting vibrations and for producing a primary electric or radio-electric signal (23) representing vibrations, and a local processing unit (13) suitable for receiving and extracting from the primary signal, at least one information item representing a duration of use of the medical device by the patient, and for producing at least one secondary signal (29) containing the information, the secondary signal being intended to be sent to at least one remote server (3) suitable for receiving and for extracting from the secondary signal, the information.

公开(公告)号：US20130225616A1

公开(公告)日：2013-08-29

申请号：US13814877

申请日：2011-08-09

申请人： Michael J.A. Walker ,  Bertrand M.C. Plouvier ,  Julian S. Northen ,  Philippe Fernandes

发明人： Michael J.A. Walker ,  Bertrand M.C. Plouvier ,  Julian S. Northen ,  Philippe Fernandes

IPC分类号： C07D471/04 ,  A61K45/06 ,  A61K31/519

CPC分类号： C07D471/04 ,  A61K31/519 ,  A61K45/06

摘要： The current invention is directed towards a polymorph of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, in the form of a crystalline solid consisting of greater than 99% by weight of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, at least 95% in the polymorphic form of a thermodynamically stable polymorph (I) of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, wherein said polymorph is determined by single crystal X-ray structural analysis and X-ray powder diffraction pattern.

摘要翻译： 本发明涉及N- {2 - [（2E）-2-（甲基咪唑基）-9,10-二甲氧基-4-氧代-6,7-二氢-2H-嘧啶并[6,1-a ] - 异喹啉-3（4H） - 基]乙基}脲，其结晶固体形式由大于99重量％的N- {2 - [（2E）-2-（甲基咪唑基）-9,10 - 二甲氧基-4-氧代-6,7-二氢-2H-嘧啶并[6,1-a]异喹啉-3（4H） - 基]乙基}脲，多晶型物的热力学稳定多晶型物的至少95％ （I）N- {2 - [（2E）-2-（甲基咪唑基）-9,10-二甲氧基-4-氧代-6,7-二氢-2H-嘧啶并[6,1-a] - 异喹啉-3 （4H） - 基]乙基}脲，其中所述多晶型物通过单晶X射线结构分析和X射线粉末衍射图确定。

公开(公告)号：US20220098229A1

公开(公告)日：2022-03-31

申请号：US17342694

申请日：2021-06-09

申请人： David J. Livingston ,  Andrew Carr ,  Philippe Fernandes

发明人： David J. Livingston ,  Andrew Carr ,  Philippe Fernandes

IPC分类号： C07H19/048

摘要： The invention relates to crystalline forms of a β-nicotinamide mononucleotide, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for nutraceutical, veterinary, and agriculturally-relevant uses.

公开(公告)号：US09062047B2

公开(公告)日：2015-06-23

申请号：US13814877

申请日：2011-08-09

申请人： Michael J. A. Walker ,  Bertrand M. C. Plouvier ,  Julian S. Northen ,  Philippe Fernandes

发明人： Michael J. A. Walker ,  Bertrand M. C. Plouvier ,  Julian S. Northen ,  Philippe Fernandes

IPC分类号： A61K31/519 ,  C07D471/04 ,  A61K45/06

CPC分类号： C07D471/04 ,  A61K31/519 ,  A61K45/06

摘要： The current invention is directed towards a polymorph of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, in the form of a crystalline solid consisting of greater than 99% by weight of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, at least 95% in the polymorphic form of a thermodynamically stable polymorph (I) of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, wherein said polymorph is determined by single crystal X-ray structural analysis and X-ray powder diffraction pattern.

摘要翻译： 本发明涉及N- {2 - [（2E）-2-（甲基咪唑基）-9,10-二甲氧基-4-氧代-6,7-二氢-2H-嘧啶并[6,1-a ] - 异喹啉-3（4H） - 基]乙基}脲，其结晶固体形式由大于99重量％的N- {2 - [（2E）-2-（甲基咪唑基）-9,10 - 二甲氧基-4-氧代-6,7-二氢-2H-嘧啶并[6,1-a]异喹啉-3（4H） - 基]乙基}脲，多晶型物的热力学稳定多晶型物的至少95％ （I）N- {2 - [（2E）-2-（甲基咪唑基）-9,10-二甲氧基-4-氧代-6,7-二氢-2H-嘧啶并[6,1-a] - 异喹啉-3 （4H） - 基]乙基}脲，其中所述多晶型物通过单晶X射线结构分析和X射线粉末衍射图确定。